These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 23090078)

  • 41. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
    Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
    Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.
    Watanabe K; Terakura S; Martens AC; van Meerten T; Uchiyama S; Imai M; Sakemura R; Goto T; Hanajiri R; Imahashi N; Shimada K; Tomita A; Kiyoi H; Nishida T; Naoe T; Murata M
    J Immunol; 2015 Feb; 194(3):911-20. PubMed ID: 25520398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Large-scale manufacturing and characterization of CMV-CD19CAR T cells.
    Wang X; Urak R; Walter M; Guan M; Han T; Vyas V; Chien SH; Gittins B; Clark MC; Mokhtari S; Cardoso A; Diamond DJ; Zaia J; Forman SJ; Nakamura R
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35027426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
    Ambrose C; Su L; Wu L; Dufort FJ; Sanford T; Birt A; Hackel BJ; Hombach A; Abken H; Lobb RR; Rennert PD
    PLoS One; 2021; 16(3):e0247701. PubMed ID: 33735268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
    Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
    Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IL-21 Selectively Protects CD62L
    Ngai H; Tian G; Courtney AN; Ravari SB; Guo L; Liu B; Jin J; Shen ET; Di Pierro EJ; Metelitsa LS
    J Immunol; 2018 Oct; 201(7):2141-2153. PubMed ID: 30111631
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.
    Fan D; Li W; Yang Y; Zhang X; Zhang Q; Yan Y; Yang M; Wang J; Xiong D
    J Hematol Oncol; 2015 Oct; 8():108. PubMed ID: 26444983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes.
    Kaka AS; Shaffer DR; Hartmaier R; Leen AM; Lu A; Bear A; Rooney CM; Foster AE
    J Immunother; 2009 Sep; 32(7):726-36. PubMed ID: 19561536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion.
    Künkele A; Brown C; Beebe A; Mgebroff S; Johnson AJ; Taraseviciute A; Rolczynski LS; Chang CA; Finney OC; Park JR; Jensen MC
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):223-232. PubMed ID: 30315942
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Saito S; Nakazawa Y; Sueki A; Matsuda K; Tanaka M; Yanagisawa R; Maeda Y; Sato Y; Okabe S; Inukai T; Sugita K; Wilson MH; Rooney CM; Koike K
    Cytotherapy; 2014 Sep; 16(9):1257-69. PubMed ID: 25108652
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
    Guedan S; Chen X; Madar A; Carpenito C; McGettigan SE; Frigault MJ; Lee J; Posey AD; Scholler J; Scholler N; Bonneau R; June CH
    Blood; 2014 Aug; 124(7):1070-80. PubMed ID: 24986688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simultaneous assessment of antigen-stimulated cytokine production and memory subset composition of memory CD8 T cells.
    Jabbari A; Harty JT
    J Immunol Methods; 2006 Jun; 313(1-2):161-8. PubMed ID: 16762359
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients.
    Casati A; Varghaei-Nahvi A; Feldman SA; Assenmacher M; Rosenberg SA; Dudley ME; Scheffold A
    Cancer Immunol Immunother; 2013 Oct; 62(10):1563-73. PubMed ID: 23903715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
    Gargett T; Truong N; Ebert LM; Yu W; Brown MP
    Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of naïve and central memory derived CD8
    Wang X; Wong CW; Urak R; Taus E; Aguilar B; Chang WC; Mardiros A; Budde LE; Brown CE; Berger C; Forman SJ; Jensen MC
    Oncoimmunology; 2016; 5(1):e1072671. PubMed ID: 26942092
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts.
    Kaiser AD; Gadiot J; Guislain A; Blank CU
    Cancer Immunol Immunother; 2013 Mar; 62(3):503-15. PubMed ID: 23001162
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.
    Schmueck-Henneresse M; Omer B; Shum T; Tashiro H; Mamonkin M; Lapteva N; Sharma S; Rollins L; Dotti G; Reinke P; Volk HD; Rooney CM
    J Immunol; 2017 Jul; 199(1):348-362. PubMed ID: 28550199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.